Early JW Therapeutics Backer Ruins Regulatory Breakthrough Party With Stake Sale 傳來重大利好，藥明巨諾卻遭淡馬錫拋棄？
The Chinese cancer drug maker’s shares surged on news of approval for its core product, only to return to earth after early investor Temasek exited 這家中國抗癌藥製造商的股價因其核心產品獲得批准而大漲，但在早期投資者淡馬錫退出後又股價回落。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.